Mark Ghobrial

Partner

Bryan Johnson

General Partner

Jeffrey Klunzinger

Managing Partner

Daniel Robinson

Partner

47 past transactions

Arzeda

Series B in 2022
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Kenota Health

Series A in 2020
Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

A-Alpha Bio

Seed Round in 2019
A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

GRO Biosciences

Seed Round in 2019
GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

uBiome

Series C in 2018
uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Verge Genomics

Series A in 2018
Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Lygos

Series B in 2018
Lygos is a Berkeley, California based biotechnology company that engineers microbes to convert sugars into high-value industrial chemicals where biological production is cost-advantaged over petrochemicals. Throughput screening and strain construction enable rapid optimization of metabolic pathways to transform cheap, renewable feedstocks into scalable chemical products. The company pursues sustainable specialty chemicals designed to replace persistent and toxic substances with safer, cleaner, cost-effective alternatives. With a multidisciplinary, vertically integrated platform, Lygos collaborates with partners across the value chain to deliver high-performing, environmentally beneficial solutions for business customers. Founded in 2011, Lygos serves B2B clients by developing and delivering products that combine performance with environmental benefits.

Catalog

Seed Round in 2018
Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

NuMat Technologies

Series B in 2018
NuMat Technologies, Inc. is a technology company based in Skokie, Illinois, specializing in the design and integration of atomically engineered materials for gas delivery, separation, and purification systems. Utilizing metal-organic frameworks (MOFs), which are nanoporous materials that can selectively interact with targeted gases and chemicals, NuMat develops advanced solutions like ION-X for the sub-atmospheric storage and delivery of hazardous implant gases. The company aims to revolutionize precision engineering by creating molecularly programmed systems that enhance resource creation and utilization. Its comprehensive platform combines material discovery software with rapid prototyping and system integration, catering to clients in sectors such as chemicals, industrials, electronics, and life sciences, thereby enabling them to meet their innovation and sustainability goals. Founded in 2012, NuMat Technologies is committed to unlocking new performance levels and production economics in its field.

Aria Pharmaceuticals

Series A in 2018
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company focused on discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Utilizing an artificial intelligence-driven drug discovery platform, Aria aims to redefine traditional drug development processes, significantly reducing the time required for discovery and increasing success rates by up to 30 times. The company builds its own pipeline of therapeutic candidates while also collaborating with biotechnology and pharmaceutical companies to identify and develop new drug candidates. Aria's innovative approach allows it to address a wide array of therapeutic areas and aims to provide breakthrough treatments for over 1,000 diseases. Founded in 2014 and based in Mountain View, California, Aria Pharmaceuticals is committed to advancing healthcare solutions for patients in urgent need.

GRO Biosciences

Seed Round in 2018
GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

3T Biosciences

Seed Round in 2017
Founded in 2017, 3T Biosciences is a biotechnology company based in Menlo Park, California. It specializes in immunotherapies for cancer treatment.

Arzeda

Series A in 2017
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Catalog

Seed Round in 2017
Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Synthego Corporation

Series B in 2017
Synthego is a biotechnology company specializing in genome engineering. It offers integrated hardware, software, bioinformatics, chemistries, and molecular biology platforms to advance basic research and therapeutic development. Its products include engineered cells, CRISPR kits, and bioinformatics tools for gene knockout, target validation, and disease modeling. Synthego serves scientists globally, with sales through distributors in multiple countries and online.

Lygos

Series A in 2016
Lygos is a Berkeley, California based biotechnology company that engineers microbes to convert sugars into high-value industrial chemicals where biological production is cost-advantaged over petrochemicals. Throughput screening and strain construction enable rapid optimization of metabolic pathways to transform cheap, renewable feedstocks into scalable chemical products. The company pursues sustainable specialty chemicals designed to replace persistent and toxic substances with safer, cleaner, cost-effective alternatives. With a multidisciplinary, vertically integrated platform, Lygos collaborates with partners across the value chain to deliver high-performing, environmentally beneficial solutions for business customers. Founded in 2011, Lygos serves B2B clients by developing and delivering products that combine performance with environmental benefits.

Prospect Bio

Seed Round in 2016
Prospect Bio is a synthetic biology company based in Brisbane, California, that specializes in developing biosensors for the detection of small molecules. These biosensors utilize living cells to perform complex chemical measurements, offering a cost-effective and scalable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. By addressing the need for improved testing solutions driven by regulatory demands, quality control, and supply chain concerns, Prospect Bio aims to transform testing processes across various industries. The company collaborates with a diverse array of partners, including major players in the wine industry, agriculture, prenatal diagnostics, and biotechnology. Its innovative approach combines microbial biotechnologies with automation and computational tools, enabling rapid biosensor and pathway discovery for medical research and other applications.

Emulate

Series B in 2016
Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

MetaMixis

Seed Round in 2016
MetaMixis Inc. specializes in the development of enzymes and metabolic pathways for microorganisms that produce chemicals. Founded in 2012 and headquartered in Vancouver, Canada, the company leverages its expertise in synthetic biology, environmental genomics, and bioinformatics to revolutionize enzyme and pathway discovery. MetaMixis creates biosensors that utilize an environment's inherent capabilities to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a multi-candidate portfolio of enzymes and pathways designed for specific target transformations. The company aims to contribute to the bioeconomy by advancing innovative solutions in biochemistry and sustainability.

Kenota Health

Seed Round in 2016
Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

Kenota Health

Seed Round in 2016
Kenota Health is a company that specializes in the development of advanced diagnostic tools for allergy testing in humans. Their innovative point-of-care system streamlines the allergy testing process by utilizing a small blood sample, which is analyzed through their equipment to detect allergen sensitization within minutes. This non-invasive technology not only simplifies the testing procedure but also provides timely results directly to healthcare providers, enhancing the overall quality of diagnostic information available to physicians. By offering a safer and more cost-effective alternative to traditional allergy testing methods, Kenota Health aims to improve patient outcomes and facilitate better healthcare decision-making.

NuMat Technologies

Series A in 2016
NuMat Technologies, Inc. is a technology company based in Skokie, Illinois, specializing in the design and integration of atomically engineered materials for gas delivery, separation, and purification systems. Utilizing metal-organic frameworks (MOFs), which are nanoporous materials that can selectively interact with targeted gases and chemicals, NuMat develops advanced solutions like ION-X for the sub-atmospheric storage and delivery of hazardous implant gases. The company aims to revolutionize precision engineering by creating molecularly programmed systems that enhance resource creation and utilization. Its comprehensive platform combines material discovery software with rapid prototyping and system integration, catering to clients in sectors such as chemicals, industrials, electronics, and life sciences, thereby enabling them to meet their innovation and sustainability goals. Founded in 2012, NuMat Technologies is committed to unlocking new performance levels and production economics in its field.

Mozio

Non Equity Assistance in 2016
Founded in 2012, Mozio operates an online platform that aggregates and compares various airport ground transportation options worldwide. Its services include shared ride shuttles, private vans, taxis, limousines, and public transit. Mozio enables travelers to search and book these services through its user-friendly interface, facilitating seamless travel from airports to final destinations.

3Scan

Series B in 2016
3Scan, Inc. is a technology company based in San Francisco, California, that specializes in the development of advanced microscopy tools and software for tissue analysis. Founded in 2011, the company focuses on automating the processes of tissue sectioning and imaging through its innovative knife-edge scanning microscopes. By integrating automation, machine learning, and computer vision, 3Scan enables researchers and medical professionals to extract spatial data from tissue samples, facilitating detailed 3D visualizations and comprehensive quantitative analysis of complex anatomical structures. This approach enhances the throughput and accuracy of tissue analysis compared to traditional histopathology, ultimately advancing the understanding of diseases that manifest at the tissue level, such as cancer, Alzheimer's, and other neurodegenerative disorders. 3Scan's technology aims to drive the discovery of new diagnostics and therapeutics in the field of biomedical research.

Elysium

Series A in 2016
Elysium Health, Inc., established in 2014 and headquartered in New York, specializes in the development and sale of health supplements. The company focuses on two primary areas: cellular health and optimization, and long-term brain health. It offers a proprietary formulation of natural compounds, designed to support overall well-being at the cellular level, which is sold directly to consumers via its online platform. Additionally, Elysium provides a biological age testing solution.

Planetary Resources

Series A in 2016
Planetary Resources specializes in asteroid mining services aimed at facilitating commercial deep space exploration. The company focuses on identifying and extracting raw materials, particularly water and precious metals, from asteroids. By harnessing these resources, Planetary Resources aims to support the development of a space economy, where water can be converted into rocket fuel and consumable supplies for human habitation beyond Earth. This approach is intended to play a crucial role in enabling humanity to evolve into a multi-planetary species, utilizing the wealth of resources available in space to fuel long-term expansion and exploration.

Nanoly

Seed Round in 2016
Nanoly Bioscience, Inc. is a biotechnology company that specializes in developing polymers designed to stabilize temperature-sensitive molecules, such as vaccines and therapeutics, during storage and transportation. Founded in 2012 and headquartered in Denver, Colorado, Nanoly's innovative polymer technology allows these sensitive products to survive without refrigeration, thereby extending their shelf life and eliminating the need for temperature-controlled storage in certain cases. This advancement is particularly significant for the distribution of vaccines and protein-based therapeutics, offering a practical solution to the challenges posed by conventional cold chain logistics.

Human Longevity

Series B in 2016
Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

Emulate

Series B in 2016
Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Pivot Bio

Series A in 2016
Founded in 2010, Pivot Bio is a biotechnology company specializing in microbial nitrogen fertilizers. It harnesses naturally occurring microbes to provide nutrients to crops sustainably, aiming to reduce the need for petrochemical fertilizers and improve crop yield.

Viv Labs

Series B in 2015
Viv Labs, Inc., established in 2012 and headquartered in San Jose, California, specializes in developing an artificial intelligence platform that facilitates interaction between users and various devices, services, and platforms through an intelligent, conversational interface. The company, formerly known as Six Five Labs, operates as a subsidiary of Samsung Research America since October 7, 2016. Viv Labs enables developers to distribute their products globally via this intuitive interface, which learns and improves daily based on user interactions.

Verge Genomics

Seed Round in 2015
Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Lucira Health

Series A in 2015
Lucira Health, Inc. is a medical technology company that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013 and based in Emeryville, California, Lucira has created a consumer-friendly, single-use testing platform that delivers centralized-laboratory-accurate molecular testing. Their flagship product is a disposable COVID-19 test kit that can be used at home, featuring a mobile application that connects users to treatment options. The kit is powered by two AA batteries and is compact enough to fit in the palm of a hand. Additionally, Lucira has developed a 2-in-1 lab testing solution that can determine if viral respiratory symptoms are due to COVID-19 or the flu, enhancing the accessibility and convenience of viral testing for consumers.

Ginkgo Bioworks

Series B in 2015
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Atomwise

Seed Round in 2015
Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Emerald Cloud Lab

Venture Round in 2015
Founded in 2010 by two scientists, Emerald Cloud Lab develops a life sciences laboratory platform designed to automate and optimize routine workflows. The company offers tools for various experiment types, aiming to accelerate innovation in the pharmaceutical sector.

Ginkgo Bioworks

Series A in 2015
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Tempo Automation Holdings

Seed Round in 2015
Tempo Automation Holdings, established in 2013 and headquartered in San Francisco, specializes in manufacturing low-volume electronics products. The company's core business involves designing and assembling printed circuit boards (PCBs) using a unique, software-automated platform. This platform enables Tempo to provide unparalleled speed, quality, and transparency, particularly during the critical prototype and new product introduction stages. Serving leading innovators across industries such as aerospace, medical technology, and automotive, Tempo Automation empowers its customers to accelerate product development and time to market.

Eat Just

Series C in 2014
Eat Just, Inc., founded in 2011 and based in San Francisco, California, focuses on creating plant-based food products aimed at improving the food system. The company offers a variety of items, including plant-based scrambled eggs, flavored mayonnaise, dressings, cookie doughs, and meat alternatives. Their flagship product, JUST Egg, has garnered significant recognition, being featured in lists such as Popular Science's "100 Greatest Innovations." Eat Just emphasizes innovation through a unique discovery platform for food ingredients, combining scientific research with culinary expertise from Michelin-starred chefs. The company has been acknowledged in various prestigious lists, including Fast Company’s "Most Innovative Companies" and Entrepreneur’s "100 Brilliant Companies."

Plethora

Series A in 2014
Plethora Corporation is a precision machining company that specializes in CNC machining, milling, and turning of various materials, including aluminum alloys, copper alloys, plastics, steels, and stainless steels. Founded in 2012 and headquartered in San Francisco, California, with an additional office in Marietta, Georgia, Plethora serves a diverse range of industries, such as robotics, automotive, aerospace, and consumer packaged goods, in the United States. The company offers innovative manufacturing systems that transform customer designs into custom parts by utilizing robotics and proprietary in-house software. Plethora also provides design feedback by analyzing CAD models directly within the client's CAD software, ensuring optimized manufacturing processes.

Miroculus

Pre Seed Round in 2014
Miroculus develops and manufactures non-invasive tools for molecular data gathering, analysis, and interpretation. Its core technology is digital microfluidics, enabling automation and miniaturization of genomic protocols like NGS library prep and synthetic biology in a compact, cartridge-based system. The company serves academic institutions, pharmaceuticals, biotechnology, and diagnostics companies, empowering them to detect and monitor diseases at the molecular level.

uBiome

Series A in 2014
uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

uBiome

Seed Round in 2014
uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Vicarious

Series B in 2014
Vicarious is an artificial intelligence company that utilizes the principles of neuro and cognitive science to create general intelligence for robots. Founded in 2010 by Dr. Dileep George and D. Scott Phoenix, Vicarious develops technology that mimics the functions of the human brain, aiming to achieve human-level intelligence in areas such as vision, language, and motor control. The company's algorithmic architecture focuses on visual perception challenges, including recognition, segmentation, and scene parsing. This innovative approach enables robot manufacturers to design robots that exhibit advanced intelligence and enhanced task efficiency, positioning Vicarious as a leader in the advancement of intelligent robotic systems.

Human Longevity

Series A in 2014
Founded in 2013, Human Longevity is a genomic-based health intelligence company headquartered in San Diego, California. It combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and empower proactive healthcare. The company's core offerings include the HLI Health Nucleus, which uses whole-genome sequence analysis and advanced clinical imaging to deliver comprehensive personal health insights.

Cleversafe

Series D in 2013
Cleversafe, Inc. is a developer of innovative web-scale storage solutions based in Chicago, Illinois. Founded in 2004, the company specializes in enterprise storage systems that enable businesses to store, manage, and access data at petabyte scale and beyond. Cleversafe's offerings include content repository, Storage-as-a-Service, enterprise collaboration, backup, and archiving solutions, catering to a diverse array of industries such as financial services, healthcare, media, oil and gas, and government sectors. The company is particularly known for its dispersed storage technology, which allows for the deployment of dispersed storage networks, providing organizations with scalable and economically efficient data storage options. Cleversafe's solutions address the challenges posed by the exponential growth of unstructured data, ensuring effective management and security while simplifying application deployment and scalability. As of November 2015, Cleversafe operates as a subsidiary of International Business Machines Corporation.

LightSail Energy

Series D in 2013
LightSail Energy focuses on the development of advanced energy storage systems that utilize compressed air technology. The company aims to modernize the electrical grid globally by providing efficient, grid-scale energy storage solutions. These systems are designed to enhance the reliability of renewable energy sources, such as solar and wind, allowing for on-demand energy delivery. By shifting its emphasis from vehicle-based technologies to large-scale applications, LightSail Energy offers clients cost-effective options for energy storage, contributing to a more sustainable energy landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.